CoChat

KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence

Open access
Amintas, Samuel, Fernandez, Benjamin, Chauvet, Alexandre, Chiche, Laurence, Laurent, Christophe, Belleannée, Geneviève, Marty, Marion, Buscail, Etienne, Dabernat, Sandrine · 2022 · Scientific Reports

Published version of a preprint

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) patients eligible for curative surgery undergo unpredictable disease relapse. Even patients with a good pathological response after neoadjuvant treatment (NAT) remain susceptible to recurrent PDAC. Molecular analysis of R0 margins may identify patients with a worse prognosis. The molecular status of mutant KRAS (exon 2, codon 12/13) was analysed retrospectively by digital droplet PCR in tumour areas, venous and resection margins of resected tumours, either undergoing up-front surgery (UFS) or after NAT with a good pathological response. Expectedly, tumour tissues or remnants from patients who underwent NAT presented lower KRAS mutant allele frequencies (MAF) than patients eligible for UFS. Similarly, ypT1 tumour MAFs were greater than the ypT0 tumour remnant MAFs in the NAT group. Mutant KRAS status in margins did not distinguish NAT subgroups. It was not predictive of shorter recurrence-free or overall survival within or between groups. KRAS -double negativity in both venous and resection margins did not identify patients with a better prognosis, regardless of the groups. The cohorts ‘sizes were small due to limited numbers of patients meeting the inclusion criteria, but KRAS -positivity or MAFs in resection and venous margins did not carry prognostic value. Comparison of margins from good versus bad responders receiving NAT may provide better clinical value.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-022-07004-x

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow chart of the two populations studied. (A) Up Font Surgery population (UFS, PANC-CTC #NCT03032913), (B) Neoadjuvant treatment (NAT) good responders. *PDAC: Pancreatic ductal adenocarcinoma.
Figure 1 Flow chart of the two populations studied. (A) Up Font Surgery population (UFS, PANC-CTC #NCT03032913), (B) Neoadjuvant treatment (NAT) good responders. *PDAC: Pancreatic ductal adenocarcinoma.CC BY · PubMed Central
Figure 2 Droplet digital PCR control samples and assessment of molecular margin KRAS positivity threshold. Droplet digital PCR Two-dimensional (2D) plots (A) Margin DNA sample negative for KRAS mutation (FA = 0.33%) (B) Margin DNA sample positive for KRAS mutation (FA = 4.7%) (C) KRAS mutant allele frequency of the 36 KRAS wild type DNA controls (Mean = 0.31 ± 0.13% with range = 0.6%). The positivity threshold was calculated as the mean + 3 SD of MAFs of the 36 samples (0.72%).*MAF: Mutant allele frequency.
Figure 2 Droplet digital PCR control samples and assessment of molecular margin KRAS positivity threshold. Droplet digital PCR Two-dimensional (2D) plots (A) Margin DNA sample negative for KRAS mutation (FA = 0.33%) (B) Margin DNA sample positive for KRAS mutation (FA = 4.7%) (C) KRAS mutant allele frequency of the 36 KRAS wild type DNA controls (Mean = 0.31 ± 0.13% with range = 0.6%). The positivity threshold was calculated as the mean + 3 SD of MAFs of the 36 samples (0.72%).*MAF: Mutant allele frequency.CC BY · PubMed Central
Figure 3 (A) Distribution of MAFs in tumour tissue from UFS group (line represents the average MAF value); Student t-test compared KRAS MAFs in sub-group of PDAC, (B) Resection margin between NAT and UFS group (p = 0.95), (C) Venous margin between NAT and UFS group (p = 0.26), (D) Tumour tissue between ypT0 and ypT1 tumour in the NAT Group (p = 0.04); (E) Resection margin between ypT0 and ypT1 (p = 0.30), (F) Venous margin between ypT0 and ypT1 (p = 0.14). *MAFs: Mutation allelic frequencies; NAT: Neoadjuvant treatment; UFS: Up-front surgery.
Figure 3 (A) Distribution of MAFs in tumour tissue from UFS group (line represents the average MAF value); Student t-test compared KRAS MAFs in sub-group of PDAC, (B) Resection margin between NAT and UFS group (p = 0.95), (C) Venous margin between NAT and UFS group (p = 0.26), (D) Tumour tissue between ypT0 and ypT1 tumour in the NAT Group (p = 0.04); (E) Resection margin between ypT0 and ypT1 (p = 0.30), (F) Venous margin between ypT0 and ypT1 (p = 0.14). *MAFs: Mutation allelic frequencies; NAT: Neoadjuvant treatment; UFS: Up-front surgery.CC BY · PubMed Central
Figure 4 Kaplan–Meier survival analysis based on the molecular resection margin status. (A) Recurrence-free survival for resection margin, (B) Overall survival for resection margin, (C) Recurrence-free survival for venous margin, (D) Overall survival for venous margin, (E) Recurrence-free survival for double-negative margin, (F) Overall survival for double-negative margin, (G) Recurrence-free survival for ypT1venous and/or resection-positive margins, (H) Overall survival for ypT1venous and/or resection-positive margins.
Figure 4 Kaplan–Meier survival analysis based on the molecular resection margin status. (A) Recurrence-free survival for resection margin, (B) Overall survival for resection margin, (C) Recurrence-free survival for venous margin, (D) Overall survival for venous margin, (E) Recurrence-free survival for double-negative margin, (F) Overall survival for double-negative margin, (G) Recurrence-free survival for ypT1venous and/or resection-positive margins, (H) Overall survival for ypT1venous and/or resection-positive margins.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 17

Metadata

Authors
Amintas, S., Fernandez, B., Chauvet, A., Chiche, L., Laurent, C., Belleannée, G., Marty, M., Buscail, E., & Dabernat, S.
Affiliations
  • Université de Bordeaux (FR)
  • Centre Hospitalier Universitaire de Bordeaux (FR)
  • Inserm (FR)
Corresponding author
Dabernat, Sandrine
Venue
Scientific Reports
Published
2022-02-22
Volume
12
Issue
1
Pages
2976-2976
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4220929504
Cited by
17
References
37
Citations by year
2026: 3 · 2025: 6 · 2024: 6 · 2023: 2
FWCI
1.46
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Fonds Patrick Brou de Laurière
  • Ligue Régionale contre le cancer
  • GIRCI-SOHO
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords
pancreatic ductal adenocarcinoma, KRAS mutation, surgical margins, recurrence, neoadjuvant therapy, pathological response, mutant allele frequency, prognosis, droplet digital PCR
MeSH terms
Margins of Excision, Aged, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Recurrence, Local, Pancreatic Neoplasms, Prognosis, Proto-Oncogene Proteins p21(ras), Neoadjuvant Therapy, Carcinoma, Pancreatic Ductal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence. https://app.cochat.ai/papers/10.1038/s41598-022-07004-x
The paper
Amintas, S., Fernandez, B., Chauvet, A., Chiche, L., Laurent, C., Belleannée, G., Marty, M., Buscail, E., & Dabernat, S. (2022). KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence. Scientific Reports. https://doi.org/10.1038/s41598-022-07004-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.